Table 5. Heterogeneity for the different pairwise meta-analyses used in the network meta-analysis.

Endpoint	Patient subgroup	Pairwise comparison	I2	Tau2	p-value
Clinical success	Adults	DAL vs VAN	76.8%	0.17	0.038
		DAP vs VAN	0%	0	0.424
		LZD vs VAN	52.5%	0.061	0.078
		TIG vs VAN	0%	0	0.964
	Mixed	LZD vs VAN	37.1%	0.032	0.146
Microbiological success	Adults	DAL vs VAN	85.6%	0.672	0.009
		DAP vs VAN	35.3%	0.221	0.213
		LZD vs VAN	63.9%	0.719	0.040
		TIG vs VAN	60.2%	0.221	0.081
	Mixed	LZD vs VAN	58.3%	0.300	0.048
Discontinuation due to AEs/SAEs	Adults	DAL vs VAN	0%	0	0.580
		DAP vs VAN	0%	0	0.660
		TIG vs VAN	61.7%	0.448	0.074
Patients with AEs	Adults	DAL vs VAN	0%	0	0.372
		DAP vs VAN	0%	0	0.516
		TIG vs VAN	0%	0	0.865
Patients with SAEs	Adults	DAL vs VAN	17.3%	0.047	0.272
		DAP vs VAN	37.5%	0.214	0.187
		TIG vs VAN	0%	0	0.394
All-cause mortality	Adults	DAL vs VAN	0%	0	0.400
		DAP vs VAN	0%	0	0.432
		LZD vs VAN	0%	0	0.810
		TIG vs VAN	0%	0	0.856

Abbreviations: DAL: dalbavancin; DAP: daptomycin; LZD: linezolid; TEI: teicoplanin; VAN: vancomycin; TIG: tigecycline.